Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting

CAMBRIDGE, U.K., and BOSTON, Mass., March 29, 2019 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta. These presentations will focus on preclinical programs that have shown target-dependent anti-tumor activity across a range of patient-derived Nectin-4 and EphA2 expressing cancer models. “Because of their small size and profound efficacy, Bicycle’s toxin conjugates are able to do what many previous antibody drug conjugate approaches could not,” said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. “Preclinical data from both our BT5528 and BT8009 programs show target-dependent anti-tumor activity across a range of EphA2-expressing and Nectin-4-expressing cancer models, respectively, and we’re proud that AACR has chosen to highlight our work.” In addition, Bicycle has also been selected to present a poster on its CD137 program, intended to activate cytotoxic T-cells, a type of cell used in the body’s immune response. Added Keen: “We believe Bicycle’s work on CD137 has produced the first fully-synthetic immune oncology modulators, which may confer several advantages over existing modalities because of the multivalency and pharmacokinetic characteristics of Bicycles.” Details on Bicycle’s presentations at the 2019 AACR Annual Meeting are as follows: Oral Presentation Title: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models Presenter: Michael Rigby, Ph.D., project leader for BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate Session Title: Novel Therapeutics Abstract: #4479 Date and Time: April 2, 2019, 3:00 p.m. – 5:00 p.m. EDT Oral Presentation Title: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models Presenter: Gavin Bennett, Ph.D., Director of Preclinical Development and project leader for BT5528, an EphA2 targeted Bicycle Toxin Conjugate Session Title: Novel Therapeutics Abstract: #4481 Date and Time: April 2, 2019, 3:00 p.m. – 5:00 p.m. EDT Poster Presentation Title: Activation of CD137 using multivalent and tumor-targeted Bicyclic peptides Presenter: Johanna Lahdenranta, Ph.D., Director of In Vivo Pharmacology Session Title: Novel Immunomodulatory Agents 1 Abstract: #3257 Date and Time: April 2, 2019, 8:00 a.m. – 12:00 p.m. EDT About Bicycle Therapeutics Bicycle Therapeutics is developing a unique class of chemically synthesised medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates®), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need. Bicycles’ small size and highly selective targeting deliver rapid tumour penetration and retention while clearance rates and routes of elimination can be tuned to minimise exposure of healthy tissue and bystander toxicities. The company’s lead program, BT1718, is being evaluated in a Phase I/IIa trial in collaboration with Cancer Research UK. The company’s unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Greg Winter, a winner of the Nobel Prize in Chemistry for his pioneering work in phage display of peptides and antibodies, and Professor Christian Heinis. Bicycle has its headquarters in Cambridge, U.K., with many key functions and members of its leadership team located in the biotech hub of Boston, Mass. For more information, visit www.bicycletherapeutics.com or follow us on Twitter at @Bicycle_tx. Contacts Media: Ten Bridge Communications Sara Green [email protected] +1-617-233-1714 Investors: Argot Partners Maeve Conneighton [email protected] +1-212-600-1902 Press Releases Close IR Nav Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources → IR Nav Overview Stock Information SEC Filings Annual General Meeting UK Annual Reports Governance + Leadership Presentation + Events Analyst Coverage Press Releases Investor Resources United Kingdom Blocks A & B Portway Building Granta Park Great Abington Cambridge CB21 6GP View Google Map United States 4 Hartwell Place Lexington, MA 02421 View Google Map General Enquiries [email protected] Follow LinkedIn Twitter Privacy © Bicycle Therapeutics 2026 Designed by Greenspace Sign up Search Close Search Search → Hello We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in Cookie Settings. Find out more Accept var s_CCSWebHostingAccount = "trcgbicycle"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/6146","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb78741\/themes\/site\/nir_pid3307"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkdFuQyEIhl-oOTbpxR6HoLLWHYUToNv69rW6pO2yZYsXCn7y8yMXBWSsFy_JAj9GC2aJBBXPnE47_hPcVPLAIhoNoiRhe065SI2oI5lWysVFIaP3FStZuB-XVxV24lmzoa7kg4RYJa1hyJuDohc-doVe8ITq_8INhsgvbCNkUErSWtfvD4Qfa5-rl9Zbx_AcjtsNj9Pp7bDgG34C5gypohlgJXX7gUvDqoNdOHUrzDRHtJV8OOxfgryTasmz4Q-KVpyApU-f5md8yy1f-866Z2rhNv8rJ2XCOg","theme":"nir_pid3307","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"364a63fdd1ba8bf28808b7d4a735dfbd500f3bdd6295cc883846cac82cce7d97"}}

The release as fetched from its publisher. bicycletherapeutics.com ↗